JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Regeneron Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

569.15 -0.48

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

566.17

Max

579.36

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-109M

809M

Pardavimai

-761M

3B

P/E

Sektoriaus vid.

14.193

40.048

Pelnas, tenkantis vienai akcijai

8.22

Dividendų pajamingumas

0.16

Pelno marža

26.701

Darbuotojai

15,158

EBITDA

-54M

1B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+28.49% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.16%

2.45%

Kitas uždarbis

2025-10-30

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-14B

60B

Ankstesnė atidarymo kaina

569.63

Ankstesnė uždarymo kaina

569.15

Naujienos nuotaikos

By Acuity

37%

63%

128 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-01 11:33; UTC

Uždarbis

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

2025-08-01 13:16; UTC

Uždarbis

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025-08-01 12:40; UTC

Uždarbis

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025-08-01 10:41; UTC

Uždarbis

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

2025-08-01 10:41; UTC

Uždarbis

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

2025-08-01 10:40; UTC

Uždarbis

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

2025-08-01 10:38; UTC

Uždarbis

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

2025-08-01 10:37; UTC

Uždarbis

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

2025-08-01 10:35; UTC

Uždarbis

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

2025-08-01 10:34; UTC

Uždarbis

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

2025-08-01 10:33; UTC

Uždarbis

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

2025-08-01 10:32; UTC

Uždarbis

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

2025-08-01 10:31; UTC

Uždarbis

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

2025-08-01 10:31; UTC

Uždarbis

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

2025-08-01 10:30; UTC

Uždarbis

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

2025-08-01 10:30; UTC

Uždarbis

Regeneron Pharma 2Q Rev $3.68B >REGN

2025-08-01 10:30; UTC

Uždarbis

Regeneron Pharma 2Q EPS $12.81 >REGN

2025-08-01 10:30; UTC

Uždarbis

Regeneron Pharma 2Q Net $1.39B >REGN

2025-06-13 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

2025-06-13 20:45; UTC

Įsigijimai, susijungimai, perėmimai

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

2025-06-13 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- Update

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

2025-06-05 01:41; UTC

Įsigijimai, susijungimai, perėmimai

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

2025-05-30 08:58; UTC

Karštos akcijos

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

2025-05-30 08:56; UTC

Rinkos pokalbiai

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

2025-05-19 17:52; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

2025-05-19 16:13; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

2025-05-19 14:42; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

Akcijų palyginimas

Kainos pokytis

Regeneron Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

28.49% į viršų

12 mėnesių prognozė

Vidutinis 718.11 USD  28.49%

Aukščiausias 900 USD

Žemiausias 543 USD

Remiantis 22 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Regeneron Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

22 ratings

15

Pirkti

6

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

542.44 / 599.76Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

128 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.